Paxlovid tied to lower risk of problems for adults with kidney disease and COVID --study

Paxlovid tied to lower risk of hospital stay, heart problems, death in adults with kidney disease and COVID The antiviral drug nirmatrelvir-ritonavir (Paxlovid) was linked to a lower risk of hospitalization within 30 days and major adverse cardiovascular events (MACEs) and death at 1 year in adults with COVID-19 and chronic kidney disease (CKD) or kidney failure, finds a study this week in Open Forum Infectious Diseases. CIDRAP

...

Patients with kidney disease are at high risk for adverse outcomes after COVID-19 despite vaccination," the study authors noted. "In addition to the acute symptoms associated with COVID-19, survivors can experience long-term effects known as 'long COVID' and are at higher risk of developing cardiovascular and kidney adverse events such as myocardial infarction, thromboembolic disease, and CKD progression."

...